This Is MS - New Tysabri Results Published in New England Journal of Medicine | Multiple Sclerosis Research, News, and Support Community

Modules

· Home
· Content
· Downloads
· Encyclopedia
· FAQ
· Feedback
· Forums
· Journal
· Private Messages
· Recommend Us
· Search
· Site_Map
· Stories Archive
· Submit News
· Surveys
· Top 10
· Topics
· Web Links
· Your Account

Google

These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS.

Languages

Select Interface Language:

Who''s Online

There are currently, 212 guest(s) and 62 member(s) that are online.

You are Anonymous user. You can register for free by clicking here

Next Step

From the creators of This is MS comes Experience Project

EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at Experience Project.

Get started by sharing your Multiple Sclerosis story.

Donations

To remain unbiased, This is MS does not accept corporate sponsorships.

Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you!

News: New Tysabri Results Published in New England Journal of Medicine

Tysabri (Antegren or Natalizumab)

With the FDA advisory committee meeting mere days away, the activity around Tysabri has become frenetic. In addition to the abstracts we posted yesterday (that will be discussed at the American Academy of Neurologists annual meeting in April), the vaunted New England Journal of Medicine just published 4 more abstracts detailing the final outcomes of the Tysabri clinical trials, as well as the PML safety follow-up.

We will provide a deeper analysis soon, but for now we wanted to get you the links to these critical new abstracts as soon as possible.

In short, Tysabri continued to demonstrate strong efficacy in terms of disability progression and relapses, a relatively low side effect profile, and (hold your breath)-- a risk of PML that has been preliminarily quantified as approximately 1 in 1000, when a person is given nearly 18 months of exposure to Tysabri. This data is of course artificially limited due to the clinical trials being halted last year; the true number can only be known in time.

Click "read more" for the links to the NEJM abstracts.

Links to NEJM Abstracts on Tysabri

Natalizumab for Relapsing Multiple Sclerosis

Natalizumab in Combination with Interferon for Relapsing Multiple Sclerosis

Evaluation of Patients Treated with Natalizumab for PML

Introductory Editorial (cuts off after 100 words)

Login

Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name.

Related Links

· More about Tysabri (Antegren or Natalizumab)
· News by Administrator

Most read story about Tysabri (Antegren or Natalizumab):
Revealing Medical History of 3rd Tysabri Patient with PML

Article Rating

Average Score: 4
Votes: 2

Options

Printer Friendly

Printer Friendly

We encourage you to also visit our Multiple Sclerosis support community on Experience Project. Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS, on the premise that no single life experience-- like having MS-- defines a person. EP now covers over 5 million true stories about every possible life experience. Find and share yours!

Network Sites: Secret Confessions | Dream Meanings | Question and Answer | Song Meanings | Baby Name Meanings
Site Map

This site does not offer medical advice. All treatment decisions should always be made with the full consent of your physician.

All logos and trademarks in this site are property of their respective owners. The comments are property of their posters, quoted articles are © referenced source, all the rest © 2002-2010 by thisisMS.com.